Publicacions en col·laboració amb investigadors/es de University of Liverpool (58)

2024

  1. Core Palliative Care Research Competencies Framework for Palliative Care Clinicians

    Journal of Palliative Medicine, Vol. 27, Núm. 4, pp. 471-480

  2. Dealing With Temporality in Patients With Life-Limiting Disease: An International Qualitative Study

    Qualitative Health Research

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

  3. What do bereaved relatives of cancer patients dying in hospital want to tell us? Analysis of free-text comments from the International Care of the Dying Evaluation (i-CODE) survey: a mixed methods approach

    Supportive Care in Cancer, Vol. 31, Núm. 1

2022

  1. Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial

    Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 2, pp. 475-485

  2. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33

  3. Dynamics in Circulating Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial

    Frontiers in Gastroenterology, Vol. 1

  4. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 7, pp. 483-494

  5. Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 65-122

  6. Live well, die well - an international cohort study on experiences, concerns and preferences of patients in the last phase of life: the research protocol of the iLIVE study

    BMJ Open, Vol. 12, Núm. 8

  7. Text mining and word embedding for classification of decision making variables in breast cancer surgery

    European Journal of Surgical Oncology, Vol. 48, Núm. 7, pp. 1503-1509

  8. The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

    Cancers, Vol. 14, Núm. 3

  9. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

    The Lancet, Vol. 399, Núm. 10319, pp. 61-116

  10. Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery

    BJS Open, Vol. 6, Núm. 1

2021

  1. Good Quality Care for Cancer Patients Dying in Hospitals, but Information Needs Unmet: Bereaved Relatives’ Survey within Seven Countries

    Oncologist, Vol. 26, Núm. 7, pp. e1273-e1284

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

    Future Oncology, Vol. 17, Núm. 11, pp. 1295-1310

  4. One chance to get it right: Improving clinical handovers for better symptom control at the end of life

    BMJ Open Quality, Vol. 10, Núm. 3

  5. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

    Journal of Hematology and Oncology